FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 750 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ΤΙ ΕΙΝΑΙ January 18, 2019 Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... September 5, 2022 England: Smoking responsible for twice as many cancers in most deprived... August 2, 2021 Cómo encontrar la fuerza interior me ayudó a recuperarme del cáncer December 30, 2020 Load more HOT NEWS Cancer Rehabilitation Starts at Diagnosis Synchronized Swimmer Learns She Has Breast Cancer After Teammate Kicks Her... FDA Approves Blood Tests That Can Help Guide Cancer Treatment Cancer Survivor And His Organ Donor Run NYC Marathon Together To...
